MGI Tech Collaborates with OncoDNA to Improve NGS Workflows
MGI Tech Co., Ltd., a leading innovator in life sciences, has joined forces with OncoDNA, a pioneer in precision medicine aimed at improving cancer treatment. This partnership focuses on the OncoDEEP® Kit, an advanced solution for Comprehensive Genomic Profiling (CGP) that integrates seamlessly into clinical workflows.
Introducing a New Era in Genomic Profiling
The collaboration aims to offer laboratories a streamlined workflow for implementing the OncoDEEP® Kit, which includes a comprehensive approach covering everything from sequencing to secondary analysis and final interpretation of next-generation sequencing (NGS) data through OncoKDM™. With its newly enhanced compatibility with MGI’s advanced sequencers, the OncoDEEP® Kit can operate smoothly across various sequencing platforms, thus providing greater flexibility for laboratories.
Leveraging Cutting-Edge Technology
In an exciting development, MGI's DNBSEQ™ technology plays a crucial role in optimizing the OncoDEEP® Kit's performance. This state-of-the-art sequencing platform utilizes DNA nanoballs (DNBs) on a patterned array chip, which significantly increases the accuracy and sensitivity of genomic data analysis. The reduction in amplification bias further boosts its utility in the precision oncology framework, making it a valuable tool for detecting solid tumors.
Comprehensive Genomic Profiling with OncoDEEP® Kit
The OncoDEEP® Kit is recognized in the industry for its extensive genomic panel that covers 638 genes and includes a total content of 1.8 Mb. This broad coverage enables laboratories to identify all pertinent genetic variants relevant to various types of solid tumors. Each gene included was carefully selected based on its biological importance and therapeutic relevance.
Key Features of the OncoDEEP® Kit
Furthermore, the OncoDEEP® Kit has been enhanced to encompass specific sequences designed to address important phenotypic regions like Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Loss of Heterozygosity (LOH) in tumor suppressor genes. Strategic targeting of intron regions for genes such as ALK, ROS1, RET, and MET-ex14 has been incorporated, allowing for comprehensive evaluation in various oncology studies.
Impact on Clinical Practices
Recent results demonstrating the efficiency of the OncoDEEP® Kit on MGI's DNBSEQ™ platform were showcased during a prominent European Congress focused on pathology. This event underscored the importance of the collaboration in pushing the boundaries of genomic profiling technologies.
Statement from OncoDNA's Visionary
Jean-Pol Detiffe, the founder of OncoDNA, expressed enthusiasm about the collaboration, stating, "Partnering with MGI marks a significant milestone in our mission to make precision oncology accessible to all. We are proud to enhance the technological landscape for laboratories while delivering superior quality to genomic profiling in clinical settings."
Maximizing Opportunities in the Oncology Field
Dr. Yong Hou, General Manager of MGI Europe and Africa, spoke about this partnership's impact on research and clinical applications, emphasizing MGI's commitment to helping partners achieve more effective results through their sophisticated sequencing platforms.
The Future of Precision Medicine
As both companies continue to innovate, they are dedicated to meeting the global demand for advanced genomic analysis solutions. OncoDNA aims to maintain its leadership role in genomics and theranostics by collaborating with elite partners and expanding their offerings across the globe.
Frequently Asked Questions
What is the OncoDEEP® Kit?
The OncoDEEP® Kit is a comprehensive genomic profiling tool designed for precision oncology, enabling the identification of relevant genetic variants in solid tumors.
How does the partnership with MGI enhance the OncoDEEP® Kit?
By integrating with MGI’s DNBSEQ™ technology, the OncoDEEP® Kit benefits from improved accuracy, sensitivity, and a streamlined workflow for laboratories.
What are the advantages of using DNBSEQ™ technology?
DNBSEQ™ technology enhances the sequencing process with reduced amplification bias, leading to more reliable genomic data crucial for cancer treatment planning.
Why is comprehensive genomic profiling important?
Comprehensive genomic profiling allows for personalized cancer treatments by identifying specific genetic mutations that can influence treatment decisions.
How can laboratories benefit from this collaboration?
Laboratories gain access to advanced genomic tools and technologies, significantly improving their capabilities in delivering precise cancer diagnosis and treatment options.
